
This month’s newsletter focuses on the latest news and scientific breakthroughs in melanoma research.
This edition features:
- Letter from AIM’s President, Sam Guild
- Notes From the Lab: Novel Targets for Immune Checkpoint Inhibitors
By Paul Bunk, Ph.D. candidate, Cold Springs Harbor Laboratory - In Plain English: Neoadjuvant Therapy for Melanoma, and How We Got Here
By Kim Margolin, M.D., FACP, FASCO - Clinical Trials Catch Up: An Interview with Joshua M.V. Mammen, M.D., Ph.D., F.A.C.S.
By Alicia Rowell, Vice President, AIM at Melanoma
Recent Posts

Sep. 17, 2023
Notes from the Lab: Novel targets for immune checkpoint inhibitors

Sep. 12, 2023
Becoming a Melanoma Caregiver…Now What? PART III with guest host, Melissa Wilson, PA-C, MPAS, UPMC Hillman Cancer Center

Sep. 07, 2023
In Plain English—Neoadjuvant Therapy for Melanoma, and How We Got Here

Aug. 28, 2023
Survivor Profile: Tricia Riffenburgh, Stage IV Melanoma

Aug. 15, 2023